Local axon degeneration is a common pathological feature of many neurodegenerative diseases, whereas the underlying molecular mechanisms are largely unknown. In this study, we used the degeneration of transected axons, termed "Wallerian degeneration," as a model to examine the possible involvement of Rho.
Axon degeneration occurs frequently in many types of chronic neurodegenerative diseases and in injuries to axons caused by toxic, ischemic, or traumatic insults (1, 2) . It may lead to separation of the neurons from their targets, resulting in the loss of neuronal function.
Effort has focused on understanding the nature of neuronal cell death in these diseases (3) , however, strategies designed to prevent neuronal cell death have resulted in only limited success in preventing or delaying neurodegeneration.
Interfering with the process of axon degeneration may represent an additional and complementary therapeutic avenue for these diseases.
The simplest model of axon degeneration known to date is the self-destructive process observed at the distal portion of a transected axon upon injury, termed "Wallerian degeneration." In vertebrates, the distal part of an axon can remain viable and conduct action potentials in vivo for up to a few days, after which they undergo rapid structural destruction in which the axolemma and axonal cytoskeleton are dismantled. Interestingly, the axons undergoing Wallerian degeneration do not seem to possess detectable activation of the caspase family cysteine proteases (4), suggesting that Wallerian degeneration and apoptosis may represent two distinct self-destruct programs.
In Wallerian degeneration slow (Wld   s   ) mice, Wallerian degeneration in response to axonal injury is delayed because of a mutation that results in the overexpression of a chimeric protein (Wld s ) composed of the ubiquitin assembly protein, Ufd2a, and nicotinamide adenine dinucleotide (NAD) biosynthetic enzyme, Nmnat1. Increased Nmnat activity was recently shown to be responsible for the axon-sparing activity of Wld s protein (5) . Downstream of Nmnat, Sirt1, a mammalian ortholog of Sir2, contributes to axonal protection. This discovery is a major step for understanding the molecular mechanism of Wallerian degeneration, however, the precise mechanism remains unknown.
Given that Wallerian degeneration is an active process, we hypothesized that the selfdestruction process of injured axons might be a type of cytoskeletal reorganization.
Rho GTPases are a family of highly related proteins best known for their effects on the actin cytoskeleton.
Here we report that Rho, a small GTPase, is involved in Wallerian degeneration in vitro and in vivo.
MATERIALS AND METHODS

Surgical procedure
Anesthetized (sodium pentobarbital, 40 mg kg -1 ) female Wistar rats (200-250 gm) received a laminectomy at vertebral level T9/10, and the spinal cord was exposed. A no. 11 blade was used for total section of the spinal cord, and a part of the spinal cord of 5mm in length was removed. A small piece of gel foam, soaked in 10 ul of 30 mM Y-27632 (Calbiochem) dissolved in PBS or PBS, was implanted into the wound cavity, and the muscle and skin layers were sutured. Histologic examination has revealed that these lesions sever all fibers in the spinal cord. The bladder was expressed by manual abdominal pressure at least twice a day.
In situ Rho GTPase activity assay -The construct consisting of the Rho GTPase binding domain of Rhotekin (nucleotides 609-857) fused with GST in the pGEX vector (RBD-GST) was kindly provided by Dr. M. A. Schwartz. In situ Rho GTPase activity assay using recombinant RBD-GST was performed as described previously (6) . Animals were fixed in 4% paraformaldehyde in 0.1 M phosphate buffer (PB) (pH 7.4) at room temperature, and the spinal cords were then dissected and fixed in 4% paraformaldehyde (PFA) in 0.1 M PB at 4 o C overnight, rinsed in PB and cryoprotected in 30% sucrose. Cryostat sections (20 um) taken from the caudal stump 10-15 mm from the transection site were incubated with blocking solution containing 5% bovine serum albumin (BSA) and 0.3% Triton X-100 in PBS for 1 hr, followed by overnight incubation with RBD-GST (2 ug/ml) at room temperature. After rinsing, sections were fixed again in 2% PFA in 0.1 M PB for 10 min at room temperature, and were incubated with an anti-GST monoclonal antibody (diluted 1:400 in blocking solution, Santa Cruz) for 1 hr at room temperature. Texas Red-conjugated anti-mouse antibody (diluted 1:500 in PBS containing 0.1% Triton X-100, Vector) was used as the secondary antibody. For quantitative analysis, we analyzed at least 3 sections per rat, 6 rats for each experimental condition. The area of corticospinal tract in the caudall stump, approximately 3-6 mm caudally from the injury site, was studied. Using Macsope analysis software (Mitani Corp.), we measured intensity of fibers. Double immunohistochemical analysis showed that the fibers shorter than 15 um were negative for neuron-specific β tubulin III, demonstrating that they were not neurons, whereas the fibers longer than 15 um were positive for neuron-specific β tubulin III. As the focus of our study is to analyze the activity of RhoA in the neurons, we selected a subset of fibers longer than 15 um. The statistical analysis was done by t-test.
In vitro degeneration assay -DRGs from P8 rats were removed and desheathed in cold sterile PBS and transferred to 6-well tissue culture dishes (Greiner) coated with polyethylenimine (Sigma). Each well contained 1 ml of culture medium consisting of Neurobasal medium (Invitrogen) supplemented with B27 (Invitrogen), 20 ng/ml NGF and 1 uM Ara C. After 3 days of incubation at 37°C in a humidified 95% air/5% CO 2 incubator, the extended neurites from explant cultures of the ganglia were transected using a microscalpel. A portion of Nogo-A encoding the 66-residue lumenal/extracellular fragment of Nogo-A was amplified by PCR and ligated into the pGEX-2T plasmid to yield a prokaryotic expression vector for the GST-Nogo fusion protein (7) . Escherichia coli strain BL21 transformed with the vectors was treated overnight at 20°C with 0.1 mM isopropylthio-b-D-galactoside to induce the protein expression. The protein was purified through a Glutathione-Sepharose 4B column (Amersham Biosciences). Expression of the protein was confirmed by Coomasie blue (CBB) staining and Western blotting using monoclonal anti-GST antibody. Immediately after the neurites of the explants were cut, Nogo-66-GST (100 nM) or GST as a control was added to the medium. Where indicated, Y-27632 was added after the transection. The explants were fixed and incubated with blocking solution containing 5% bovine serum albumin (BSA) and 0.3% Triton X-100 in PBS for 1 hr, followed by an overnight incubation at 4 o C with anti-beta-III tubulin antibody (diluted 1:1000 in blocking solution. Covance.)
Fluorescent dye Alexa Fluor 488 conjugated anti-mouse IgG (diluted 1:1000 in PBS containing 0.1% Triton X-100, Molecular Probe) was used as the secondary antibody. Quantitative analysis of axonal degeneration was performed, and the cultures were examined using phase-contrast as well as fluorescence microscopy. Axons with a fragmented, non-refractile appearance were designated as "degenerated". At least 200 individually distinguishable axons were blindly scored from several random images of each culture. Each condition was tested in triplicate explants in each experiment. Results were obtained from 3-4 independent experiments for each condition. Statistical analysis was performed by Student's t-test.
Growth cone collapse assay -Explants of DRG were transected using a microscalpel, incubated for 2 hours on the dishes, and were treated for 30 minutes with the GST-Nogo fusion protein at 100 nM. Explants were fixed in 4% (wt/vol) paraformaldehyde, and were stained with fluorescence-labeled phalloidin (Sigma). For each experiment, we assessed at least 100 growth cones, and repeated the same experiments three times.
Immunohistochemistry -The transected spinal cords were fixed in 4% PFA in 0.1 M PB for 1 hr at room temperature, and cryostat sections were prepared.
They were incubated with blocking solution containing 5% bovine serum albumin (BSA) and 0.3% Triton X-100 in PBS for 1 hr, followed by an overnight incubation at 4 o C with anti-beta-III tubulin antibody (diluted 1:1000 in blocking solution. Covance.) or anti-neurofilament antibody (diluted 1:200 in blocking solution. Chemicon).
Fluorescent dye Alexa Fluor 488 conjugated anti-mouse IgG (diluted 1:1000 in PBS containing 0.1% Triton X-100, Molecular Probe) was used as the secondary antibody.
Anterograde labeling of the CST -Descending CST fibers were labeled with biotin dextran amine (BDA, 10% in saline, 3.5 µl per cortex, MW 10,000; Molecular Probes, Eugene, OR) injected under anesthesia at the left and the right motor cortices (coordinates: 2 mm posterior to bregma, 2 mm lateral to bregma, 1.5 mm depth). For each injection, 0.25 µl of BDA was delivered over 30 seconds via a 15-20 µm inner diameter glass capillary attached to a microliter syringe (ITO). We examined 5 control and 5 Rho-kinase inhibitortreated rats with the spinal cord injury. Fourteen days after BDA injection, the animals received the spinal cord injury (total section of the spinal cord) and were treated with or without Rho-kinase inhibitor. Five days after surgery, the rats were killed by perfusion with PBS followed by 4% paraformaldehyde. The spinal cords were dissected, post-fixed overnight in the same fixatives, and cryopreserved in 30% sucrose in PBS. The spinal cord 5 mm rostral and 5 mm caudal to the lesion site (10 mm long) was embedded in Tissue Tek OCT. These blocks were sectioned in the sagittal plane (50 µm), retaining each section. Transverse sections were also collected from the spinal cord rostral and caudal to the injury site. Sections were blocked in PBS with 0.5% BSA for 1 hour and then incubated for 1 day with Alxa Fluor 488-conjugated streptavidin (1:400; Molecular Probes) in PBS with 0.15% BSA.
For quantification, BDA-labeled axons were counted on every fifth section and the total number of counted fibers was multiplied by 5 to generate an estimated total number of labeled axons caudal or rostral to the injury site. Statistical analysis was performed using Student's t-test.
Affinity-precipitation of GTP-RhoA -Cells were lysed in 50mM Tris (pH7.5), containing 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 500mM NaCl and 10 mM MgCl 2 , with leupeptin and aprotinin, each at 10 µg/ml. Cell lysates were clarified by centrifugation at 13,000 g at 4°C for 10 minutes, and the supernatants were incubated with 20 µg of RBD-GST beads at 4°C for 45 minutes. The beads were washed 4 times with a washing buffer (50mM Tris (pH7.5) containing 1% Triton X-100, 150mM NaCl, 10 mM MgCl 2 , 10 µg/ml each of leupeptin and aprotinin). Bound Rho proteins were detected by Western blotting using a monoclonal antibody against RhoA (Santa Cruz Biotech., Santa Cruz, CA, USA).
RESULTS
Rho activation in injured axons
It has been reported that RhoA is activated in neurons and glial cells around the injury site following spinal cord injury (8, 9) . This activation is dependent on the p75 receptor, which transduces the signal from several myelinderived inhibitors of axon regeneration, during the early stages. As these myelin-derived proteins are present around the injured axons, we were interested in changes in Rho activity in the injured fibers that lead to Wallerian degeneration. The rat spinal cord was injured at the thoracic level by transecting the spinal cord. The animals were sacrificed 8 or 24 hrs after surgery, and the tissues caudal to the injury site were removed. To examine the Rho activity after spinal cord injury, the in situ pull-down method was employed (6) . We incubated sections with a recombinant Rho GTPase binding domain of Rhotekin fused with GST (GST-RBD), and cells that bound high levels of RBD were detected with an anti-GST antibody. In sham-operated animals, no significant signal for Rho activation was observed (Fig.  1a) , however, we observed intensively stained fibers in the white matter where descending projections were localized 8 (Fig. 1b) or 24 hrs (Fig.  1c) after spinal cord injury. The signal was significantly more intensive in the injured animals than in the sham-operated animals by quantitating the signal intensity in the corticospinal tract caudal to the injury site (Fig. 1d) . Thus, Rho is activated extensively in injured axons distal from the lesion site.
Myelin-derived
proteins accelerate axon degeneration by activating Rho/Rho-kinase in vitro Rho activation after spinal cord injury is partly mediated by growth-inhibitory proteins from myelin, including Nogo-A, myelinassociated glycoprotein and oligodendrocytemyelin glycoprotein (10) .
These proteins are believed to inhibit the regeneration of injured axons in the central nervous system. These growthinhibitory proteins may contribute to the degeneration of axons by activating RhoA. To test this hypothesis, we employed an in vitro degeneration model of transected axons from cultured primary neurons. Degeneration of the distal part of neurites was assessed after transection in P8 rat DRG explants cultured for 3 days.
The distal part of neurites was separated from the body of the explant using a microscalpel and followed for up to 24 hrs after transection. The severed axons began to develop signs of early degeneration such as focal swelling and beading approximately 8 hrs after the axons had been separated from their cell bodies (Fig. 2a) .
We first examined if these neurites, separated from the cell bodies for 2 h, were still responsive to these proteins. The effects of Nogo-66-GST on neuronal growth cones were assessed. Bath applications of Nogo-66-GST (100 nM) for 30 min exhibited significant growth cone collapsing activity (Fig. 2f) .
We then measured RhoA activity in the neurons. Using the RhoA-binding domain of the effector protein Rhotekin, the GTP-bound form of RhoA can be affinityprecipitated. The assay revealed that RhoA was activated 30 minutes following the addition of Nogo-66-GST to the culture (Fig. 2g) . Thus, these neurites are responsive to Nogo-66 after separation from the cell bodies.
We next tested if these proteins play a role in the degeneration of severed distal axons. In the presence of 100nM Nogo-66-GST, the axons completely degenerated and detached 8 hrs postaxotomy (Fig. 2b) .
The relative number of remaining neurites was significantly decreased by the Nogo-66 treatment compared to the control (Fig. 2e) . To test whether the effect of Nogo-66-GST is dependent on the activation of Rho and its downstream effector, Rho-kinase, in neurites, the explants were treated with a Rho-kinase inhibitor, Y-27632. Although Y-27632 itself had no effect on the degeneration of the distal part of neurites (Figs. 2c, e) , it completely abolished the effect of Nogo-66-GST (Figs. 2d, e) . As Y-27632 had no significant effect on basal axonal degeneration, RhoA may be inactive in the control DRG, which is also suggested by the affinity-precipitation data (Fig.  2g) . The same result was achieved with the soluble form of myelin-associated glycoprotein (data not shown). These results suggest that myelin-derived proteins facilitate axonal degeneration following axotomy by activating Rho/Rho-kinase in vitro.
Rho-kinase inhbition suppresses Wallerian degeneration in vivo
To assess whether the observations from in vitro culture experiments were valid in vivo, we first performed immunostaining experiments to examine the alterations of microtubules or neurofilaments in the injured spinal cords. An early step of Wallerian degeneration is the granular disintegration of the cytoskeleton, in which the normal cytoskeletal proteins of the axon are abruptly degraded to granular and amorphous debris. Three days after the spinal cord lesion, sections from one segment above and below the lesion site displayed clear signs of Wallerian degeneration. Staining for neuron-specific beta-III tubulin protein demonstrated a massive loss of nerve fibers (Fig. 3a, Supplementary Figs. 1 and  2) . Furthermore, many pathological profiles were visible with a swollen and irregular appearance. To examine whether the Rho-kinase inhibitor retards Wallerian degeneration in vivo, we applied gel foams, pre-soaked with the vehicle (PBS) or Y-27632, to the lesion sites and examined the spinal cords 3 days post-axotomy by immunostaining.
As expected, Y-27632 significantly abolished the breakdown of microtubules (Figs. 3a, b, Supplementary Figs. 1  and 2 ) and neurofilaments (Fig. 3c, d ) as well as axolemma in transected spinal cords. These results suggest that the inhibition of Rhokinase activity can delay Wallerian degeneration both in vitro and in vivo.
Finally, the integrity of the dorsal corticospinal tract (CST) in rats with spinal cord injury was visualized by injecting biotin-dextran amine (BDA) into the sensory-motor cortex to demonstrate Wallerian degeneration more clearly. The spinal cord was injured 14 days after the injection of BDA, and the rats were sacrificed and morphologically assessed 5 days after the injury. Labeled CST fibers rostral to the lesion site in longitudinal sections showed numerous intact fibers (Figs. 4a) . However, very few labeled fibers with a dot-like appearance were seen caudal to the injury site, demonstrating extensive degeneration of the axons (Figs. 4b, d) . However, we observed that However, we observed that samples from injured rats treated with the Rho-kinase inhibitor exhibited an entirely different pattern of labeling (Figs. 4c, d) , clearly showing that fiber degeneration was significantly inhibited by the Rho-kinase inhibitor.
DISCUSSION
The breakdown of neurofilaments depends on an influx of Ca 2+ and the activation of the Ca 2+ -dependent protease, calpain (11) . Inhibition of the ubiquitin proteosome system delays axon degeneration both in vitro and in vivo (12) , although the molecular target of ubiquitin proteosome system-mediated proteolysis is unknown.
In contrast, a recent surprising study showed that increased NAD biosynthesis or enhanced activity of the NAD-dependent deacetylase SIRT1 protects mouse neurons from Wallerian degeneration using mice carrying a spontaneous dominant Wld s mutation (5). It is possible that the target of SIRT1 protective activity may be a transcriptional factor upregulating the expression of neuroprotective proteins.
We started current study by hypothesizing that degeneration of the axons is a process of cellular cytoskeleton alteration. Our study adds a new participant in Wallerian degeneration, although the link to previous findings remains unknown.
As Rho plays a key role in regulating the actin cytoskeleton, our data support the notion that local axon destruction is the process of cytoskeletal reorganization. However, it is noted that the Rho-kinase inhibitor only partially prevented Wallerian degeneration. Therefore, other molecular events should play important roles in the phenomenon. In addition, we used spinal cord injury model to assess it in the current study.
As Wallerian degeneration is robust in the peripheral neurons, it is important to assess if Rho-kinase inhibitors slow down degeneration of the peripheral neurons. However, we failed in detecting activation of RhoA in the injured axons following sciatic nerve (8, 13) . Thus, Rho/Rho-kinase has important roles in the pathogenesis of spinal cord injury.
The morphological features of Wallerian degeneration are common to a spectrum of neurodegenerative disorders. In addition, axonal degeneration also occurs during normal development (1) . Neurons in the brain initially extend axonal branches to inappropriate regions, and these branches are later lost by a process called pruning.
It was reported very recently that cell-specific ablation of the murine gene Ptk2, encoding focal adhesion kinases, increases the number of axonal terminals and synapses formed by neurons in vivo (16) . Focal adhesion kinases seem to contribute to the negative regulation of axonal branching through the activation of Rho by p190 Rho guanine nucleotide-exchange factor. Therefore, molecular events underlying the process of axon destruction in developmental and pathological states might be at least partly common. Possible crosstalk between the activation of the Rho/Rho-kinase pathway and NAD-SIRT1 or ubiquitin proteosome system should be assessed in the future. Manipulating the process of axon degeneration may represent a therapeutic avenue for neurodegenerative diseases with axon destruction. (a~d) DRG explants were cultured for 3 days and then cut. Note the degeneration of neurites distal from the cut site 8 hrs after separation (a). After transection of the neurites, the cultures were incubated with Nogo-66-GST (100 nM) or GST as a control for 8 h. Degeneration was facilitated by Nogo-66-GST (100 nM). (b), and the effect of Nogo-66-GST was inhibited by Y-27632 (3 uM) (d). (e) Quantitative analysis of the number of remaining neuritis relative to pre-transection. Data are the mean ± S.E.M. of 3 independent experiments. Asterisks indicate statistical significance compared to the control, *; p<0.01 (Student's t-test). (f) Results of growth cone collapse assays. Nogo-66-GST (100 nM) or GST as a control is used for the treatment. Data are mean ± S.E. An asterisk indicates statistical significance. *, p < 0.01 (Student's t-test). (g) Affinity precipitation of RhoA in the DRG. RhoA activity was increased 30 min after the addition of Nogo-66-GST (100 nM) to the explant cultures. 
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